Nasal Drug Delivery

SNBL’s nasal drug delivery platform is a proprietary system consisting of powder carrier technology and delivery device technology.

Expertise in Nasal Delivery

3D Nasal Cast Model



SNBL seeks to establish strategic partnership of our nasal drug delivery technology with pharmaceutical companies. After conducting a evaluation program to fulfill client’ s needs, as shown as below, we would license our technology (e.g. by compound, indication, area of application, nation/region, etc.).

Licensee of Platform Technology

Satsuma Pharmaceuticals, Inc. (USA)

Satsuma Pharmaceuticals, Inc. (Satsuma) was established in the US by SNBL primarily for the purpose of furthering the development of a migraine treatment drug (dihydroergotamine, DHE) applying SNBL licensing platform technology related to the development of a nasal DHE product (STS101).


Satsuma was listed on the NASDAQ in the United States on September 13, 2019.

Satsuma is currently conducting two Phase III clinical trials for STS101 (EMERGE and ASCEND) and are planning on submitting results to the FDA for approval in the first quarter of 2023.


If STS101 proceeds to market according to the current development plan, sales royalties will be awarded to SNBL, Ltd. per licensing agreement between the two companies.